This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Juventas Therapeutics, Inc.
Drug Names(s): ACRX-100, MyoCell SDF-1
Description: JVS-100 is a plasmid that encodes Stromal Cell-derived Factor-1 (SDF-1). SDF-1 is thought to inhibit cell death, recruit stem cells that repair tissue, and promote blood flow. JVS-100 is injected into multiple sites of the left ventricular heart muscle using a percutaneous needle injection catheter.
Deal Structure: JVS-100 was originally developed by AcelleRX Therapeutics. AcelleRX changed its name to Juventas Therapeutics.
Additional information available to subscribers only: